Abigail Cline1,2,3, Andrew Berg1,2,3, Gregory J Bartos1,2,3, Lindsay C Strowd1,2,3, Steven R Feldman1,2,3. 1. Drs. Cline, Berg, and Bartos are with the Center for Dermatology Research at the Wake Forest School of Medicine in Winston-Salem, North Carolina. 2. Dr. Strowd is with the Department of Social Sciences & Health Policy at the Wake Forest School of Medicine. 3. Dr. Feldman is with the Department of Dermatology at University of Southern Denmark in Odense, Denmark.
Abstract
Background and Objectives: Severe, recalcitrant cases of pediatric psoriasis or atopic dermatitis may necessitate treatment with biological agents; however, this may be difficult due to lack of treatment options and standardized treatment guidelines. This review evaluates the biological treatment options available, including off-label uses, and provides a basic therapeutic guideline for pediatric psoriasis and atopic dermatitis. Materials and Methods: A PubMed review of biological treatments for pediatric psoriasis and atopic dermatitis with information regarding age, efficacy, dosing, contra-indications, adverse events, and off-label treatments. Results: Currently there are three European Medicines Agency (EMA)-approved biological treatment options for pediatric psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently Food and Drug Administration (FDA)- and EMA-approved for adult atopic dermatitis, it is still not yet approved for pediatric atopic dermatitis. Conclusion: Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients.
Background and Objectives: Severe, recalcitrant cases of pediatric psoriasis or atopic dermatitis may necessitate treatment with biological agents; however, this may be difficult due to lack of treatment options and standardized treatment guidelines. This review evaluates the biological treatment options available, including off-label uses, and provides a basic therapeutic guideline for pediatric psoriasis and atopic dermatitis. Materials and Methods: A PubMed review of biological treatments for pediatric psoriasis and atopic dermatitis with information regarding age, efficacy, dosing, contra-indications, adverse events, and off-label treatments. Results: Currently there are three European Medicines Agency (EMA)-approved biological treatment options for pediatric psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently Food and Drug Administration (FDA)- and EMA-approved for adult atopic dermatitis, it is still not yet approved for pediatric atopic dermatitis. Conclusion: Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients.
Authors: Kelly M Cordoro; Derya Ucmak; Maria Hitraya-Low; Michael D Rosenblum; Wilson Liao Journal: JAMA Dermatol Date: 2017-01-01 Impact factor: 10.282
Authors: Ian Landells; Colleen Marano; Ming-Chun Hsu; Shu Li; Yaowei Zhu; Lawrence F Eichenfield; Peter H Hoeger; Alan Menter; Amy S Paller; Alain Taieb; Sandra Philipp; Philippe Szapary; Bruce Randazzo Journal: J Am Acad Dermatol Date: 2015-08-07 Impact factor: 11.527
Authors: Amy S Paller; Elaine C Siegfried; David M Pariser; Kara Creamer Rice; Mona Trivedi; Jan Iles; David H Collier; Greg Kricorian; Richard G Langley Journal: J Am Acad Dermatol Date: 2016-02 Impact factor: 11.527
Authors: Caren Garber; Malcolm Creighton-Smith; Eric P Sorensen; Nicole Dumont; Alice B Gottlieb Journal: J Drugs Dermatol Date: 2015-08 Impact factor: 2.114
Authors: Diamant Thaçi; Eric L Simpson; Lisa A Beck; Thomas Bieber; Andrew Blauvelt; Kim Papp; Weily Soong; Margitta Worm; Jacek C Szepietowski; Howard Sofen; Makoto Kawashima; Richard Wu; Steven P Weinstein; Neil M H Graham; Gianluca Pirozzi; Ariel Teper; E Rand Sutherland; Vera Mastey; Neil Stahl; George D Yancopoulos; Marius Ardeleanu Journal: Lancet Date: 2015-10-08 Impact factor: 79.321